This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lehmensiek, V. Articles by Tumani, H. Search for Related Content PubMed PubMed Citation Articles by Lehmensiek, V. Articles by Tumani, H. Social Bookmarking                   What's this?

Cerebrospinal fluid proteome profile in multiple sclerosis

Department of Neurology, University of Ulm, 89081 Ulm, Germany

SD Süssmuth

Department of Neurology, University of Ulm, 89081 Ulm, Germany

G. Tauscher

Department of Neurology, University of Ulm, 89081 Ulm, Germany

J. Brettschneider

Department of Neurology, University of Ulm, 89081 Ulm, Germany

S. Felk

Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, 88397 Biberach an der Riss, Germany

F. Gillardon

Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, 88397 Biberach an der Riss, Germany

H. Tumani

Department of Neurology, University of Ulm, 89081 Ulm, Germany, hayrettin.tumani{at}uni-ulm.de

Cerebrospinal fluid (CSF) proteins may provide important information about the pathomechanisms present in multiple sclerosis (MS). Although diagnostic criteria for early MS are available, there is still a need for biomarkers, predicting disease subtype and progression to improve individually tailored treatment. Using the two-dimensional difference gel electrophoresis (2-D-DIGE) technology for comparative analysis, we compared CSF samples from patients with MS of the relapse-remitting type (RRMS, n = 12) and from patients with clinically isolated syndrome (CIS, n = 12) suggestive of a first demyelinating attack with neurologically normal controls. Protein spots that showed more than two-fold difference between patients and controls were selected for further analysis with MALDI-TOF mass spectrometry. Immunoblot analysis was performed to confirm the validity of individual candidate proteins. In RRMS, we identified 1 up-regulated and 10 down-regulated proteins. In CIS, 2 up-regulated and 11 down-regulated proteins were identified. One of these proteins (Apolipoprotein A1) was confirmed by immunoblot. Though the pathophysiological role of these proteins still remains to be elucidated in detail and further validation is needed, these findings may have a relevant impact on the identification of disease-specific markers. Multiple Sclerosis 2007; 13: 840—849. http://msj.sagepub.com

Key Words: cerebrospinal fluid • clinically isolated syndrome • multiple sclerosis • proteomics • relapse-remitting • 2-D gel electrophoresis

Multiple Sclerosis, Vol. 13, No. 7, 840-849 (2007)
DOI: 10.1177/1352458507076406


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Rithidech, L Honikel, M Milazzo, D Madigan, R Troxell, and L. Krupp Protein expression profiles in pediatric multiple sclerosis: potential biomarkers Multiple Sclerosis, April 1, 2009; 15(4): 455 - 464. [Abstract] [PDF]